.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Dow
Baxter
Harvard Business School
US Department of Justice
Mallinckrodt
Cerilliant
McKesson
Medtronic
Chinese Patent Office

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,476,010

« Back to Dashboard

Which drugs does patent 8,476,010 protect, and when does it expire?


Patent 8,476,010 protects DIPRIVAN and is included in one NDA.

Protection for DIPRIVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,476,010

Title:Propofol formulations with non-reactive container closures
Abstract: A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
Inventor(s): Desai; Neil P. (Pacific Palisades, CA), Yang; Andrew (Rosemead, CA), Ci; Sherry Xiaopei (San Marino, CA)
Assignee: APP Pharmaceuticals LLC (Schaumburg, IL)
Application Number:10/616,709
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Fresenius Kabi Usa
DIPRIVAN
propofol
INJECTABLE;INJECTION019627-002Jun 11, 1996ABRXYesYes8,476,010*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Dow
Queensland Health
QuintilesIMS
Argus Health
Teva
Fuji
Merck
UBS
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot